PUBLICATIONS

PUBLICATIONS AND PRESENTATIONS

OPHTHALMOLOGY

2017

  1. Ahmed I, Navratil T, Semba C, Talamo J. “Highlighting Successful Technologies in Sustained Drug Delivery in Ophthalmology: New Polymer Science and Particle Engineering Platforms that Drive Future Promising Extended Release Therapies”. ARVO Special Interest Group, May 2017.
  2. Mansberger S, Conley J, Verhoeven R, Blackwell K, Depenbusch M, Knox T, Walters T, Ahmed I, Yerxa B, Navratil T. “Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Durations Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515”. ARVO abstract and poster presentation, May 2017.
  3. Navratil T, Conley J, Verhoeven R, Blackwell K, Nadkarni A, Trevino L, Yerxa B, Depenbusch M, Knox T, Ahmed I, Walters T, Mansberger S. “Extended PGA Delivery Results in Significant Dose Sparing Compared to PGAs and Achieves Sustained IOP Lowering for 11 Months Without Any Loss of Efficacy”. ARVO abstract and poster presentation, May 2017.
  4. Owens G, Sandahl M, Tully J, Haley J, Caesar K, Williams S, Verhoeven R, Garcia A, Navratil T, Yerxa B. “Extended Release Aflibercept with Sustained Vitreous Concentration in Non-Human Primates from Biodegradable Hydrogel Implants”. ARVO abstract and poster presentation, May 2017.
  5. Robeson R, Verhoeven R, Garcia A, Das S, Hamby K, Hernandez M, Gum G, Yerxa B, Navratil T. A 12-Month Study of the Effect of ENV515 (travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs”. ARVO abstract and poster presentation, May 2017.
  6. Sandahl M, Caesar K, Tully J, Yang M, Williams S, Schiffman R, Yerxa B. In Vitro Sustained Release of Tyrosine Kinase Inhibitors from Biodegradable PRINT Implants”. ARVO abstract and poster presentation, May 2017.
  7. Tully J, Yang M, Williams S, Das S, Verhoeven R, Robeson R, Schiffman R, Yerxa B. In Vitro and In Vivo Sustained Release of Dexamethasone from Intravitreal Implants”. ARVO abstract and poster presentation, May 2017.
  8. Williams S, Verhoeven R, Melton D, Tully J, Das S, Robeson R, Garcia A, Yang M, Yerxa B. “Nonclinical Development of an Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema”. ARVO abstract and poster presentation, May 2017.
  9. Verhoeven R, Williams S, Tully J, Das S, Robeson R, Navratil T, Yerxa B. “Nonclinical Development of ENV1105, an Intravitreal Dexamethasone Extended Release Implant for the Treatment of Diabetic Macular Edema”. ASCRS abstract and poster presentation, May 2017.
  10. Walters T, Conley J, Blackwell K, Verhoeven R, Garcia A, Nadkarni A, Das S, Trevino L, Yerxa B, Ahmed I, Mansberger S, Navratil T. “Low Dose ENV515 Travoprost XR Demonstrated 9 Month Duration after a Single Dose and Matched IOP-Lowering Effects of Pre-Study Prostaglandin Analogs and In-Study Timolol”. ASCRS abstract and podium presentation, May 2017.
  11. Mansberger S, Navratil T, Conley J, Ahmed I, Walters T, Yerxa B. “Interim Analysis of Low Dose ENV515 Travoprost XR with 9 Month Duration and IOP-Lowering Effects of Pre-Study PGAs and In-Study Timolol” American Glaucoma Society (AGS) abstract and podium presentation, March 2017.
  12. Nadkarni A, Delgado J, Garcia A, Willard G, Verhoeven R, Trevino L, Ahmed I, Walters T, Navratil T, Mansberger S. “Design and Development of ENV515 Intraocular Applicator Including Custom Needle for Intracameral Injections of ENV515 Travoprost Extended Release (XR) Therapy for Glaucoma”. American Glaucoma Society (AGS) abstract and poster presentation, March 2017.
  13. Navratil T, Conley J, Verhoeven R, Ahmed I, Walters T, Mansberger S, Yerxa B. “Changing the Paradigm of PGA Dosing in Glaucoma with Extended Release Formulations: Continuous PGA Release Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 9 Months without Any Attenuation in IOP Lowering Effect” American Glaucoma Society (AGS) abstract and poster presentation, March 2017.

2016

  1. Yerxa B. “ENV515 Travoprost XR for Glaucoma: Clinical Development Update”. ISOPT Clinical presentation, December 2016.
  2. Walters T, Navratil T, Pittman S, Conley J, Trevino L, Silverstein B, Depenbusch M, Ahmed I, Mansberger S, Schiffman R, Yerxa B. “Interim 9 Month Safety and Efficacy of Intracameral Low Dose ENV515 Travoprost XR from an Ongoing 12-Month Phase 2a Study in Glaucoma Patients”. AAO Abstract and Poster, October 2016.
  3. Das S, Williams S, Tully J, Verhoeven R, Owens G, Robeson R, Hansen J, Yang M, Navratil T, Schiffman R. “Precision Size and Shape Extended Release Intravitreal Dexamethasone Implants”. ARVO Abstract and Poster Presentation, May 2016.
  4. Navratil T, Delgado J, Garcia A, Willard G, Corson A, Verhoeven R, Trevino L, Schiffman R. “Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy”. ARVO Abstract and Poster Presentation, May 2016.
  5. Owens G, Sandahl M, Hernandez M, Tully J, Garcia A, Williams S, Navratil T, Schiffman R. “Extended Release of anti-VEGF Biologics from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration”. ARVO Abstract and Poster Presentation, May 2016.
  6. Robeson R, Verhoeven R, Garcia A, Miller P, Miller J, Navratil T, Schiffman R. “A 6-Week Toxicity and Toxicokinetic Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits”. ARVO Abstract and Poster Presentation, May 2016.
  7. Sandahl M, Hernandez M, Tully J, Owens G, Verhoeven R, Robeson R, Williams S, Schiffman R. “In vitro and In vivo Sustained Release of Dexamethasone from a PRINT Microparticle Suspension”. ARVO Abstract and Poster Presentation, May 2016.
  8. Tully J, Yang M, Sandahl M, Williams S, Schiffman R. “Sustained Release Biodegradable Formulations for Intraocular Delivery: Extended Release of Hydrophilic APIs and Combination Products”. ARVO Abstract and Poster Presentation, May 2016.
  9. Verhoeven R, Robeson R, Garcia A, Gilger B, Culp D, Struble C, Hamm L, Grizzle T, Navratil T, Schiffman R. “A 6-Week Ocular Pharmacokinetic Study of ENV905 (Difluprednate) Ophthalmic Implantor Durezol in the Albino Rabbit”. ARVO Abstract and Poster Presentation, May 2016.
  10. Walters T, Navratil T, Pittman S, Conley J, Trevino L, Silverstein B, Depenbusch M, Mansberger S, Schiffman R. “Completed 28-Day and Interim 3-Month Analysis of the Ongoing 12-Month Safety and Efficacy Evaluation of Low Dose ENV515 (travoprost) Intracameral Implant in Phase 2 Study”. ARVO Abstract and Poster Presentation, May 2016.

2015

  1. Mansberger SL, Navratil T, Barnes M, Walters TR, Silverstein BE, Silverstein SM, Pearce JH, DuBiner HB, Durham T, Conley J, Berdahl JP, Price FW, Ahmed IK, Pepose JS, Yerxa BR. First-Time-in-Human Safety and Efficacy Evaluation of Intracameral ENV515 Travoprost XR in Glaucoma Patients. AAO Abstract and Poster Presentation, November 2015.
  2. Walters TR, Navratil T, Silverstein BE, Durham T, Barnes M, Berdahl JP, Ahmed IK, Mansberger SL, Pepose JS, Yerxa BR. Development and Validation of a Novel Clinical Trial Design for Extended-Release Intracameral Therapies for Glaucoma. AAO Abstract and Paper Presentation, November 2015.
  3. Verhoeven RS, Garcia A, Hansen J, Conley J, Robeson R, Gilger BC, Navratil T, Yerxa B. “Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery”. ESCRS Abstract and Presented Poster, August 2015.
  4. Struble C, Yerxa B, Navratil T, Garcia A, Verhoeven RS, Hu Y, Lam T, To W, Charles SA, Perlroth V. “Improvements in Technologies to Maintain Sustained Levels of Ophthalmic Drugs in the Eye: PRINT Particles and Novel Bioconjugates”. ISOPT Abstract and Podium Presentation, June 2015.
  5. Das S, Williams SS, Tully JE, Verma A, Hansen J, Hernandez M, Pegoraro T, Navratil T, Maynor BB, Yerxa B. “Sustained Release Biodegradable Steroid Formulations for Intravitreal Delivery”. ARVO Abstract and Poster Presentation, May 2015.
  6. Garcia A, Verhoeven RS, Pegoraro T, Hansen J, Conley J, Robeson R, Gilger BC, Navratil T, Yerxa B. “Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery”. ARVO Abstract and Poster Presentation, May 2015.
  7. Navratil T, Garcia A, Verhoeven RS, Trevino L, Gilger BC, Mansberger SL, Budenz DL, Ahmed IK, Lewis RA, Yerxa B. “Advancing ENV515 (travoprost) Intracameral Implant for Glaucoma into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study”. ARVO Abstract and Poster Presentation, May 2015.
  8. Owens G, Williams SS, Herlihy KP, Tully JE, Verhoeven RS, Navratil T, Maynor BB, Yerxa B. “Establishing In Vivo to In Vitro Correlations for the Rate of Release of Bevacizumab from Extended Release Formulations”. ARVO Abstract and Poster Presentation, May 2015.
  9. Trevino L, Hunter M, Das S, Pegoraro T, Massey T, Garcia A, Tully JE, Hamby K, Navratil T, Yerxa B. “The Aseptic Fabrication of ENV515 Intracameral (Travoprost) Implants”. ARVO Abstract and Poster Presentation, May 2015.
  10. Tully JE, Williams SS, Herlihy KP, Owens G, Fawcett G, Meye N, Navratil T, Maynor BB, Yerxa B. “In Vitro Release of Bevacizumab from Hydrogel-based Drug Delivery Systems”. ARVO Abstract and Poster Presentation, May 2015.
  11. Verhoeven RS, Williams SS, Conley J, Owens G, Lawrence MS, Navratil T, Yerxa B. “Extended Release Bevacizumab Intravitreal Implant is Well Tolerated in the African Green Monkey”. ARVO Abstract and Poster Presentation, May 2015.
  12. Williams SS, Das S, Hansen J, Tully JE, Hernandez M, Pegoraro T, Verhoeven RS, Maynor BB, Yerxa B. “Fabrication of Shape and Size Specific Nanoparticles for Ocular Drug Delivery”. ARVO 2015
  13. Williams SS, Herlihy KP, Owens G, Tully JE, Verhoeven RS, Navratil T, Maynor BB, Yerxa B. “Biodegradable Extended Release Bevacizumab Intravitreal Implants”. GTC 7th Ocular Diseases Drug Discovery Abstract and Poster Presentation, March 2015.

2014

  1. Navratil T, Maynor BB, Yerxa B. “Improving Outcomes in Ophthalmology via Sustained Drug Delivery”. On Drug Delivery: Ophthalmic Drug Delivery, No. 48, April 10 2014.
  2. Garcia A, Tully JE, Das S, Pegoraro T, Trevino L, Maynor BB, Navratil T, Yerxa B. “Precisely Engineered Biodegradable Drug Delivery Systems for the Extended Release of Prostaglandin Analogues in the Anterior Chamber”. ARVO Abstract and Poster Presentation, May 2014.
  3. Herlihy KP, Williams SS, Owens G, Savage J, Gardner L, Robeson R,
    Maynor BB, Navratil T, Gilger BC, Yerxa B. “Extended Release of Microfabricated Protein Particles from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration”. ARVO Abstract and Poster Presentation, May 2014.
  4. Maynor BB, Garcia A, Tully JE, Williams SS, Herlihy KP, Owens G, Robeson R, Navratil T, Gilger BC, Yerxa B. “Development of Precisely-Engineered Biodegradable Drug Delivery Systems for Posterior Ocular Drug Delivery: PRINT® PLGA Extended Release Implants for anti-VEGF Biologics”. ARVO Abstract and Poster Presentation, May 2014.
  5. Navratil T, Garcia A, Tully JE, Trevino L, Hunter M, Stoltz D, Robeson R, Maynor BB, Ahmed IK, Budenz DL, Lewis RA, Mansberger SL, Gilger BC, and Yerxa B. “Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant – Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action”. ARVO Abstract and Podium Presentation, May 2014.
  6. Savage J, Herlihy KP, Williams SS, Owens G, Robeson R, Maynor BBB, Navratil T, Gilger BC, Yerxa B. “Biodegradable Hydrophobic Intravitreal Implants for the Extended Release of Bevacizumab for Age Related Macular Degeneration”. ARVO Abstract and Poster Presentation, May 2014.
  7. Trevino L, Navratil T, Robeson R, Garcia A, Tully JE, Hunter M, Stoltz D, Maynor BB, Powell K, Crean C, Gilger BC, Yerxa B. “Intracameral Conversion of Travoprost to Travoprost Acid in the Normotensive Beagle Dog Model”. ARVO Abstract and Poster Presentation, May 2014.
  8. Verma A, Kindig J, Sebastian K, Tully JE, Garcia A, Robeson R, Maynor BB, Navratil T, Gilger BC, Yerxa B. “Controlled and Extended Release of Difluprednate from Biodegradable Intraocular Implants Engineered using PRINT® Technology”. ARVO Abstract and Poster Presentation, May 2014.
  9. Williams SS, Herlihy KP, Owens G, Nuzum M, Hunter S, Schorzman D, Savage J, Gardner L, Robeson R, Garcia A, Tully JE, Maynor BB, Navratil T, Yerxa B. “Photocurable Hydrogel Implants for the Extended Release of Bevacizumab for the Treatment of Age Related Macular Degeneration”. ARVO Abstract and Poster Presentation, May 2014.

2013

  1. Garcia A, Tully JE, Maynor BB, Yerxa B. “Precisely Engineered Biodegradable Intraocular Implants for the Sustained Release of Dexamethasone”. ARVO Abstract and Poster Presentation, May 2013.
  2. Maynor BB, Garcia A, Tully JE, Yerxa B. “Application of PRINT Microparticle and Nanoparticle Technology – Toward Preparation of Ophthalmic Suspension Formulations with Improved Tolerability and Efficacy”.  ARVO Abstract and Poster Presentation, May 2013.

 

PRINT

  1. Xu J, Wong DHC, Byrne JD, Chen K, Bowerman C, DeSimone JM. “Future of Particle Replication of Non-Wetting Templates (PRINT) Technology”. Angewandte Chemie Int. 2013, 52, 6580-6589.
  2. Merkel TJ, Chen K, Jones SW, Napier ME, Zamboni WE, DeSimone JM. “The Effect of Particle Size on the Biodistribution of Low-modulus Hydrogel PRINT Particles”. J Controlled Release. 2012, 162, 37-44.
  3. Wang Y, Byrne JD, Napier ME, DeSimone JM. “Engineering Nanomedicines Using Stimuli-responsive Biomaterials”. Advanced Drug Delivery Reviews. 2012, 64(11), 1021-1030.
  4. Garcia A, Mack P, Williams SS, Fromen C, Shen T, Tully J, Pillai J, Kuehl P, Napier M, DeSimone JM, Maynor BB.“Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and Other Pharmaceutical Applications”. J Drug Delivery. Volume 2012, 2012.
  5. Galloway AL, Murphy A, Rolland JP, Herlihy KP, Petros RA, Napier MA, DeSimone JM. “Micromolding for the Fabrication of Biological Microarrays” in Biological Microarrays: Methods and Protocols; Eds A. Khademhosseini; K.-Y Suh; M. Zourob; 2011, 249-260.
  6. Canelas DA, Herlihy KP, DeSimone JM. “Top-down Particle Fabrication: Control of Size and Shape for Diagnostic Imaging and Drug Delivery”. Advanced Reviews Wiley. 2009, 1 (4), 391-404.
  7. Kelly JY, DeSimone JM. “Shape-specific, Mono-disperse Nano-molding of Protein Particles”; J Am Chem Soc. 2008, 130, 5438-5439.
  8. Gratton SEA, Williams SS, Napier ME, Pohlhaus PD, Zhou Z, Wiles KB, Maynor BB, Shen C, Olafsen T, Samulski ET, DeSimone JM. “The Pursuit of a Scalable Nano-fabrication Platform for Use in Material and Life Science Applications”. Accounts of Chemical Research. 2008, 41, 1685-1695.
  9. Rolland JP, Maynor BB, Euliss LE, Exner AE, Denison GM, DeSimone JM. “Direct Fabrication and Harvesting of Monodisperse, Shape Specific Nano-Biomaterials”; J Am Chem Soc. 2005, 127, 10096-10100.
Copyright 2013 Envisia Therapeutics